Valuation: Roche Holding AG

Capitalization 256B 328B 278B 242B 449B 30,380B 457B 2,997B 1,175B 14,727B 1,232B 1,206B 51,904B P/E ratio 2026 *
17.2x
P/E ratio 2027 * 15.9x
Enterprise value 265B 340B 288B 251B 465B 31,468B 473B 3,104B 1,217B 15,254B 1,276B 1,249B 53,762B EV / Sales 2026 *
4.23x
EV / Sales 2027 * 3.99x
Free-Float
87.84%
Yield 2026 *
3.13%
Yield 2027 * 3.22%
1 day-0.55%
Current month-1.49%
3 months-8.24%
6 months+12.95%
Current year-3.26%
Current year 315.6
Extreme 315.6
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 14/03/2023
Director of Finance/CFO 59 05/06/2011
Chief Tech/Sci/R&D Officer 59 09/02/2025
Director TitleAgeSince
Director/Board Member 67 31/12/1995
Chairman 59 14/03/2023
Director/Board Member 73 02/03/2015
Change 5d. change 1-year change 3-years change Capi.($)
-0.55%+1.39% - - 328B
+2.55%-1.32%+10.37%+150.23% 830B
-0.15%-1.79%+48.71%+44.08% 564B
-0.29%+0.21%+20.46%+29.26% 369B
-1.27%-0.43%+47.18%+24.26% 318B
+3.13%-1.94%+52.65%+4.33% 294B
-0.84%-2.39%+29.84%+33.57% 291B
+1.69%+1.22%+28.13%+44.31% 192B
-1.62%+7.81%-34.14%-54.07% 182B
-0.66%-0.97%+31.66%+63.64% 171B
Average -0.46%+0.05%+26.10%+37.74% 356.67B
Weighted average by Cap. -0.39%-0.61%+27.21%+58.73%

Financials

2026 *2027 *
Net sales 62.69B 80.43B 68.13B 59.33B 110B 7,442B 112B 734B 288B 3,607B 302B 295B 12,715B 64.77B 83.1B 70.39B 61.3B 114B 7,689B 116B 759B 297B 3,727B 312B 305B 13,137B
Net income 15.14B 19.42B 16.45B 14.33B 26.55B 1,797B 27.02B 177B 69.52B 871B 72.86B 71.34B 3,070B 15.63B 20.05B 16.98B 14.79B 27.41B 1,855B 27.89B 183B 71.77B 899B 75.21B 73.65B 3,170B
Net Debt 9.16B 11.75B 9.96B 8.67B 16.07B 1,087B 16.35B 107B 42.07B 527B 44.09B 43.17B 1,858B 2.42B 3.1B 2.63B 2.29B 4.24B 287B 4.32B 28.32B 11.11B 139B 11.64B 11.4B 490B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
20/04/26 317.70 CHF -0.72% 212,981
17/04/26 320.00 CHF +2.07% 1,381,401
16/04/26 313.50 CHF -1.10% 1,098,440
15/04/26 317.00 CHF -0.35% 1,120,333
14/04/26 318.10 CHF +0.28% 744,438
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
320.00CHF
Average target price
352.62CHF
Spread / Average Target
+10.19%

Quarterly revenue - Rate of surprise